Tandem Diabetes Care, Inc. (TNDM) – What Are Analysts Thinking About This Stock?

by · The Markets Daily

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) have received a consensus recommendation of “Hold” from the twenty-three ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $27.08.

Several analysts have recently commented on TNDM shares. William Blair assumed coverage on shares of Tandem Diabetes Care in a research report on Friday, August 21st. They issued an “outperform” rating on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Tandem Diabetes Care in a research note on Tuesday, September 8th. Citigroup cut their price objective on Tandem Diabetes Care from $24.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, September 30th. Truist Financial reduced their target price on Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, September 24th. Finally, UBS Group started coverage on Tandem Diabetes Care in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $18.00 target price on the stock.

Check Out Our Latest Stock Analysis on Tandem Diabetes Care

Tandem Diabetes Care Stock Up 0.9%

Shares of TNDM stock opened at $16.38 on Tuesday. The company has a quick ratio of 2.65, a current ratio of 3.18 and a debt-to-equity ratio of 4.62. The firm’s 50-day moving average is $18.83 and its two-hundred day moving average is $17.89. Tandem Diabetes Care has a 12 month low of $12.26 and a 12 month high of $29.65.

Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical device company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.01. Tandem Diabetes Care had a negative net margin of 6.08% and a negative return on equity of 45.97%. The business had revenue of $254.56 million for the quarter, compared to analyst estimates of $254.99 million. During the same period in the previous year, the firm earned ($0.78) EPS. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Equities research analysts anticipate that Tandem Diabetes Care will post -0.66 EPS for the current fiscal year.

Hedge Funds Weigh In On Tandem Diabetes Care

A number of institutional investors have recently made changes to their positions in TNDM. Leonteq Securities AG lifted its position in Tandem Diabetes Care by 21.7% in the 1st quarter. Leonteq Securities AG now owns 9,501 shares of the medical device company’s stock valued at $182,000 after acquiring an additional 1,695 shares in the last quarter. Diversified Trust Co boosted its stake in Tandem Diabetes Care by 9.1% in the 1st quarter. Diversified Trust Co now owns 21,332 shares of the medical device company’s stock worth $409,000 after purchasing an additional 1,774 shares during the period. OP Asset Management Ltd bought a new position in Tandem Diabetes Care during the 1st quarter worth about $35,000. Integrated Wealth Concepts LLC bought a new position in Tandem Diabetes Care during the 2nd quarter worth about $33,000. Finally, 180 Wealth Advisors LLC increased its holdings in Tandem Diabetes Care by 17.3% during the 1st quarter. 180 Wealth Advisors LLC now owns 15,763 shares of the medical device company’s stock worth $302,000 after purchasing an additional 2,320 shares in the last quarter.

Tandem Diabetes Care Company Profile

(Get Free Report)

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to work with continuous glucose monitoring (CGM) systems and digital health tools to help automate and personalize insulin therapy.

Tandem’s product portfolio includes the t:slim X2 insulin pump, which features a rechargeable design and software that supports automated insulin delivery. The company also offers the t:slim X2 pump with Control-IQ technology, an algorithm designed to adjust insulin delivery based on CGM readings, and the compact Tandem Mobi pump.

Recommended Stories